Reported about 10 hours ago
Merck has announced its acquisition of UK-based Verona Pharma for approximately $10 billion, aimed at enhancing its portfolio beyond the blockbuster cancer drug Keytruda, which faces patent expirations starting in 2028. The acquisition, Merck's largest since 2023, is seen as a strategic move to secure future revenue, particularly with Verona's newly approved COPD treatment, Ohtuvayre, projected to generate multibillion-dollar revenue by the mid-2030s.
Source: YAHOO